Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics Statistics

Total Valuation

CLDX has a market cap or net worth of $1.66 billion. The enterprise value is $883.11 million.

Market Cap	1.66B
Enterprise Value	883.11M

Important Dates

The next estimated earnings date is Tuesday, November 12, 2024, after market close.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

CLDX has 66.29 million shares outstanding. The number of shares has increased by 18.94% in one year.

Current Share Class	66.29M
Shares Outstanding	66.29M
Shares Change (YoY)	+18.94%
Shares Change (QoQ)	+12.14%
Owned by Insiders (%)	0.28%
Owned by Institutions (%)	107.16%
Float	66.10M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	171.41
Forward PS	932.73
PB Ratio	2.07
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	106.36
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 29.36, with a Debt / Equity ratio of 0.00.

Current Ratio	29.36
Quick Ratio	29.06
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -27.53% and return on invested capital (ROIC) is -18.61%.

Return on Equity (ROE)	-27.53%
Return on Assets (ROA)	-17.83%
Return on Capital (ROIC)	-18.61%
Revenue Per Employee	$51,894
Profits Per Employee	-$938,850
Employee Count	160
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -2.27% in the last 52 weeks. The beta is 1.59, so CLDX's price volatility has been higher than the market average.

Beta (5Y)	1.59
52-Week Price Change	-2.27%
50-Day Moving Average	34.57
200-Day Moving Average	37.60
Relative Strength Index (RSI)	27.09
Average Volume (20 Days)	908,118

Short Selling Information

The latest short interest is 8.40 million, so 12.67% of the outstanding shares have been sold short.

Short Interest	8.40M
Short Previous Month	8.31M
Short % of Shares Out	12.67%
Short % of Float	12.70%
Short Ratio (days to cover)	5.40

Income Statement

In the last 12 months, CLDX had revenue of $8.30 million and -$150.22 million in losses. Loss per share was -$2.68.

Revenue	8.30M
Gross Profit	-112.64M
Operating Income	-163.29M
Pretax Income	-150.22M
Net Income	-150.22M
EBITDA	-160.19M
EBIT	-163.29M
Loss Per Share	-$2.68

Balance Sheet

The company has $802.32 million in cash and $2.39 million in debt, giving a net cash position of $799.93 million or $12.07 per share.

Cash & Cash Equivalents	802.32M
Total Debt	2.39M
Net Cash	799.93M
Net Cash Per Share	$12.07
Equity (Book Value)	813.66M
Book Value Per Share	12.28
Working Capital	784.32M

Cash Flow

In the last 12 months, operating cash flow was -$121.49 million and capital expenditures -$1.44 million, giving a free cash flow of -$122.93 million.

Operating Cash Flow	-121.49M
Capital Expenditures	-1.44M
Free Cash Flow	-122.93M
FCF Per Share	-$1.85

Margins

Gross Margin	n/a
Operating Margin	-1,966.65%
Pretax Margin	-1,809.18%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-1,480.75%

Dividends & Yields

CLDX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.94%
Shareholder Yield	-18.94%
Earnings Yield	-8.93%
FCF Yield	-7.30%

Analyst Forecast

The average price target for CLDX is $64.83, which is 159.17% higher than the current price. The consensus rating is "Buy".

Price Target	$64.83
Price Target Difference	159.17%
Analyst Consensus	Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	126.86%
EPS Growth Forecast (5Y)	-8.56%

Stock Splits

The last stock split was on February 11, 2019. It was a reverse split with a ratio of 0.0666666:1.

Last Split Date	Feb 11, 2019
Split Type	Reverse
Split Ratio	0.0666666:1

Scores

CLDX has an Altman Z-Score of 34.97 and a Piotroski F-Score of 4.

Altman Z-Score	34.97
Piotroski F-Score	4